Recurrence of Graves’ Disease: What Genetics of HLA and PTPN22 Can Tell Us

BACKGROUND: Approximately half of patients diagnosed with Graves’ disease (GD) relapse within two years of thyreostatic drug withdrawal. It is then necessary to decide whether to reintroduce conservative treatment that can have serious side effects, or to choose a radical approach. Familial forms of...

Descripción completa

Detalles Bibliográficos
Autores principales: Vejrazkova, Daniela, Vcelak, Josef, Vaclavikova, Eliska, Vankova, Marketa, Zajickova, Katerina, Vrbikova, Jana, Duskova, Michaela, Pacesova, Petra, Novak, Zdenek, Bendlova, Bela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650699/
https://www.ncbi.nlm.nih.gov/pubmed/34887833
http://dx.doi.org/10.3389/fendo.2021.761077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650699/
https://www.ncbi.nlm.nih.gov/pubmed/34887833
http://dx.doi.org/10.3389/fendo.2021.761077

Ejemplares similares